MRK - Cue Biopharma: CUE-101's Phase 1 Promising Progress 1 New IND Expected Funding Until Q2 2022
- Cue Biopharma is a clinical-stage biopharmaceutical company developing novel injectables that modulate targeted T-cells.
- Cue Biopharma has expanded its pipeline to include 7 therapeutics with 1 undergoing clinical trials (CUE-101). CUE-101 is Cue's lead therapeutic halfway through Phase 1 and targeting HPV-related cancers.
- With its early-stage pipeline, Cue Biopharma isn't expected to reach commercialization until 2025 when the forecasted EPS reaches $0.21/share on top of revenues of $185.5M. 2019 revenues were $1.1M.
- Cue Biopharma's near-term catalyst is the interim/phase 2 dosage data from CUE-101 coming in 1H'21 and CUE-102's IND filing under the LG Chem partnership by 2H'21.
- In summary, the author projects Cue Biopharma as a "buy" at a 1-year price target of $15.60 (+27% upside) and a 5-year price target of $52.50 (+329% upside).
For further details see:
Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022